Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non-cash Items (2019 - 2025)

Arcturus Therapeutics Holdings' Non-cash Items history spans 7 years, with the latest figure at $13.3 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 44.19% year-over-year to $13.3 million; the TTM value through Dec 2025 reached $13.3 million, up 44.19%, while the annual FY2025 figure was $13.3 million, 44.19% up from the prior year.
  • Non-cash Items reached $13.3 million in Q4 2025 per ARCT's latest filing, up from $9.2 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $53.3 million in Q4 2023 to a low of $9.2 million in Q4 2024.
  • Average Non-cash Items over 5 years is $26.7 million, with a median of $13.3 million recorded in 2025.
  • Peak YoY movement for Non-cash Items: skyrocketed 397.11% in 2023, then plummeted 82.65% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $47.1 million in 2021, then crashed by 77.24% to $10.7 million in 2022, then skyrocketed by 397.11% to $53.3 million in 2023, then tumbled by 82.65% to $9.2 million in 2024, then surged by 44.19% to $13.3 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Non-cash Items are $13.3 million (Q4 2025), $9.2 million (Q4 2024), and $53.3 million (Q4 2023).